CPHI Online is part of the Informa Markets Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Home Research & Development News Rexahn Pharmaceuticals announces new data for Supinoxin showing potent tumour growth inhibition
News
15 Dec 2015

Rexahn Pharmaceuticals announces new data for Supinoxin showing potent tumour growth inhibition

New data demonstrate Supinoxin dose dependently inhibits tumour cell growth in a preclinical model of triple negative breast cancer.

Rexahn Pharmaceuticals has presented new preclinical data for its anti-cancer compound, Supinoxin (RX-5902) at the 38th Annual San Antonio Breast Cancer Symposium (SABCS) in San Antonio, Texas.

The company's presentation, entitled "The Anti-Cancer Effects of Supinoxin (RX-5902) in Triple Negative Breast Cancer MDA-MB-231 Through Phosphorylated p68 on Tyr593" was co-authored by Frances Fuller-Pace, Division of Cancer Research, University of Dundee, UK and Rexahn scientists.

Building on recent data presented by Rexahn at the American Association for Cancer Research Annual Meeting, which demonstrated the ability of Supinoxin to dose-dependently decrease the migration of human triple negative breast cancer cells (MDA-MD-231) in a preclinical model of cancer cell metastasis, Rexahn scientists presented new data at the SABCS showing potent tumour inhibition effects of Supinoxin in a preclinical xenograft mouse model of human triple negative breast cancer (TNBC).

  • The results demonstrated that oral administration of ascending weekly doses of Supinoxin of 160, 320 and 600 mg/kg showed dose-dependent, potent tumour growth inhibition of 44%, 65% and 83%, respectively, and extended the overall survival of these animals. Moreover, by comparison, 5 mg/kg of Abraxane administered by intravenous injection achieved 50% tumour inhibition.

    Dr Fuller-Pace commented: "The accumulating data for Supinoxin suggest that it targets a unique protein that may play a prominent role in an important biological pathway that leads to the growth and metastasis of cancerous cells and therefore is a promising new potential anti-cancer therapeutic. The current survival and tumour inhibition data in the TNBC model are particularly intriguing as this patient population represents a subset of breast cancer patients with high unmet medical need. We look forward to continuing to build on this promising body of data."

    "We are very pleased to see potent tumour inhibition effects in a well validated preclinical model following oral administration of Supinoxin," said Dr Ely Benaim, Chief Medical Officer for Rexahn. "Supinoxin is currently being evaluated in an ongoing Phase I multi-center, dose-finding, open-label, single agent clinical study in patients with advanced or metastatic solid tumours. Recently presented data from the Phase I trial showed promising preliminary evidence of clinical activity. We look forward to additional data from this study."

    • Related tags
    Research & Development

    Related News